CANARIABIO


Associated tags: HER2, Cancer, Antibody, PSA, MUC1, Neoplasm, Patient, Oregovomab, Pharmaceutical industry, Ovarian cancer, Carboplatin, Paclitaxel, Safety, Survival, Immunization

Locations: SOUTH KOREA, BRAZIL, BELGIUM, ARGENTINA, HUNGARY, ITALY, INDIA, US, CHILE, KOREA, SEOUL, MEXICO, POLAND, ROMANIA, TAIWAN, SPAIN, CZECH REPUBLIC, CANADA

Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy

Retrieved on: 
Thursday, October 12, 2023
III, Partnership, HR, Oregovomab, Survival, Ovarian cancer, Carboplatin, Paclitaxel, Immune system, AU, Progression-free survival, Patient, Pharmaceutical industry, Nursing

SINGAPORE and SEOUL, South Korea, Oct. 12, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) has signed a license deal with Korea-based CanariaBio Inc., acquiring the exclusive license to a new monoclonal antibody therapy for patients with ovarian cancer in Australia, New Zealand and in select Southeast Asian countries.

Key Points: 
  • Exclusive license for AU, NZ, Singapore, Malaysia, Brunei, Thailand and Vietnam
    SINGAPORE and SEOUL, South Korea, Oct. 12, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) has signed a license deal with Korea-based CanariaBio Inc., acquiring the exclusive license to a new monoclonal antibody therapy for patients with ovarian cancer in Australia, New Zealand and in select Southeast Asian countries.
  • Announcing the partnership, ST Chief Executive Officer Carlo Montagner said he was pleased CanariaBio had selected ST as a partner for this highly promising therapy.
  • "ST has a portfolio of anti-cancer therapies targeting multiple solid tumours with the exception of ovarian cancer, and now oregovomab becomes our first ovarian cancer agent," Mr Montagner said.
  • At CanariaBio, we've always believed in the transformative power of partnerships, and teaming up with ST reinforces this belief."

CanariaBio and Hikma announce the signing of distribution and license agreement for oregovomab in MENA Region

Retrieved on: 
Tuesday, October 10, 2023
Patient, HR, Paclitaxel, Progression-free survival, Carboplatin, Oregovomab, Film industry

SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC (Hikma), today announced the signing of distribution and license agreement for oregovomab in the Middle East and North Africa (MENA) region.

Key Points: 
  • SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC (Hikma), today announced the signing of distribution and license agreement for oregovomab in the Middle East and North Africa (MENA) region.
  • "We are thrilled to partner with Hikma, a company with a strong presence in the MENA region and a proven track record of successful collaborations," said Michael Na, CEO of CanariaBio.
  • Oregovomab is being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer in the phase 3 FLORA-5 trial.
  • In Phase 2, the addition of oregovomab yielded a median progression-free survival of 41.8 months compared with 12.2 months with standard chemotherapy (HR, 0.46, P=0.0027).

CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer

Retrieved on: 
Monday, August 21, 2023
Pancreatic cancer, Marketing, ODD, Cancer, Malignancy, Patient, MUC1, Diagnosis, Rare, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Vaccine, Pharmaceutical industry

PYEONGTAEK, South Korea, Aug. 21, 2023 /PRNewswire/ -- CanariaBio Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative immunotherapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its investigational drug product, MAb-AR20.5, an IgG1k type murine monoclonal antibody that binds specifically to the circulating and tumor-associated antigen (MUC1) expressed ubiquitously on pancreatic cancer cells. This milestone marks the first monoclonal antibody targeting Mucin 1 (MUC1) to receive this designation for pancreatic cancer.

Key Points: 
  • This milestone marks the first monoclonal antibody targeting Mucin 1 (MUC1) to receive this designation for pancreatic cancer.
  • Pancreatic cancer remains one of the most challenging malignancies to treat, with limited therapeutic options available.
  • The MAb-AR20.5 has shown potential in early studies, by inducing MUC-1-specific immune responses in cancer patients with advanced disease.
  • CanariaBio Inc. is planning to initiate clinical trials to assess the safety and efficacy of MAb-AR20.5 in patients with pancreatic cancer.

CanariaBio Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination with Niraparib in the Treatment of Recurrent Ovarian Cancer

Retrieved on: 
Tuesday, August 8, 2023
GSK, Ovarian cancer, KOSDAQ, Niraparib, Immunization, Recurrence, PARP, Patient, PFS, ADP, Pharmaceutical industry, Oregovomab

SEOUL, S.KOREA, Aug 8, 2023 - (ACN Newswire) - CanariaBio, a KOSDAQ-listed and a leading late-stage biotechnology company, announces the successful enrollment completion of a Phase 2 study of Oregovomab in combination with niraparib, GSK's poly (ADP-ribose) polymerase (PARP) inhibitor, for treatment of patients with platinum-sensitive recurrent ovarian cancer.

Key Points: 
  • SEOUL, S.KOREA, Aug 8, 2023 - (ACN Newswire) - CanariaBio, a KOSDAQ-listed and a leading late-stage biotechnology company, announces the successful enrollment completion of a Phase 2 study of Oregovomab in combination with niraparib, GSK's poly (ADP-ribose) polymerase (PARP) inhibitor, for treatment of patients with platinum-sensitive recurrent ovarian cancer.
  • This trial, known as FLORA-4 (NCT05335993), is being conducted by CanariaBio, with GSK providing clinical trial supply of niraparib.
  • The study will assess the immunological and clinical activity, early humoral response, and disease control rate of concomitant Oregovomab and daily oral niraparib.
  • This will be a preliminary investigation of the interaction of indirect immunization with Oregovomab and concomitant niraparib therapy and the immune modulatory effects associated with PARP inhibition.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022
Death, Patient, Biotechnology, HER2/neu, MUC1, Gynaecology, Trial of the century, Immunization, Cancer, Immunoglobulin G, Terminology, GOG, PSA, Risk, Overalls, Immunotherapy, Toxicity, Antibody, Oregovomab, Survival, Paclitaxel, FRCPC, Leadership, Safety, MH, Carboplatin, Drug combination, Ovarian cancer, Cancer immunology, Pharmaceutical industry

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022
Death, View, Patient, Biotechnology, HER2/neu, MUC1, Gynaecology, Trial of the century, Immunization, Cancer, Multimedia, Immunoglobulin G, Terminology, GOG, PSA, Risk, Overalls, Immunotherapy, Toxicity, Antibody, Oregovomab, Survival, Paclitaxel, FRCPC, Leadership, Safety, MH, Carboplatin, Drug combination, Ovarian cancer, Cancer immunology, Pharmaceutical industry

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.